TuHURA Biosciences (NASDAQ:HURA) Coverage Initiated at Maxim Group

Maxim Group assumed coverage on shares of TuHURA Biosciences (NASDAQ:HURA) in a report published on Tuesday, Marketbeat Ratings reports. The firm issued a buy rating and a $15.00 price target on the stock.

TuHURA Biosciences Price Performance

Shares of NASDAQ:HURA opened at $4.92 on Tuesday. TuHURA Biosciences has a 12-month low of $2.84 and a 12-month high of $23.73. The firm has a market cap of $7.82 million, a price-to-earnings ratio of -0.03 and a beta of 0.82.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.